Conditions: Non-Hodgkin's Lymphoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 55
Healthy volunteers: no

Brief summary:
This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).

Detailed description:

Arms:
arm 1: 500 milligrams (mg), oral, daily (QD), up to six (6) 28-day cycles

Interventions: intervention 1: LY317615
Intervention descriptions: intervention 1: 500 mg, oral, QD, up to six 28 day cycles

Protocol document: